MMP-3-1171 5A/6A Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis - supplementary material

<b>Supplementary material 1:</b><b> </b><b>Figures S1-S6</b><b>Fig. S1:</b> Forest plot indicating the association of <i>MMP-3-1171</i> (5A/6A) polymorphism with overall cancer susceptibility in the different genetic models.<b>Fig. 2:</b><b> </b>Sensitivity plot for detecting the association of <i>MMP-3-1171</i> (5A/6A) polymorphism and overall cancer risk.<b>Fig. S3:</b> Funnel plots indicating the publication bias for detecting the association of <i>MMP-3-1171</i> (5A/6A) polymorphism with the overall cancer susceptibility<b>Fig. S4:</b> Trial sequential analysis for <i>MMP-3</i><i>-1171 </i><i>(5A/6A) </i>in allele model of the overall meta-analysis.<b>Fig. S5:</b> Box plots of <i>MMP-3</i> gene expression between tumor and normal tissue in ten cancer types using GEPIA2 web server ((*<i>p</i> ≤ 0.05); <b>T:</b> Tumor tissues; <b>N: </b>Normal tissues; <b>BRCA: </b>Breast invasive carcinoma; <b>ESCA:</b> Esophageal carcinoma; <b>STAD:</b> Stomach adenocarcinoma; <b>COAD: </b>Colon adenocarcinoma; <b>CESC:</b> Cervical squamous cell carcinoma and endocervical adenocarcinoma; <b>OV:</b> Ovarian serous cystadenocarcinoma; <b>HNSC:</b> Head and Neck squamous cell carcinoma; <b>LUAD:</b> Lung adenocarcinoma; <b>LUSC:</b> Lung squamous cell carcinoma; <b>LIHC: </b>Liver hepatocellular carcinoma)).<b>Fig. S6:</b><b> Impact of MMP3 expression level on the survival of different types of cancer patients generated from UALCAN database ( </b><b>https://ualcan.path.uab.edu/analysis.html</b><b> )</b><b>Table S1</b>: Genotype and data information of the selected studies for meta-analysis to detect the association of <i>MMP-3</i> ‑1171 5A/6A with cancer risk<b>Table S2.</b> Quality assessment of the included studies by NOS<br><br>